Molecular Imaging Research in the Outcomes Era. Measuring Outcomes for Individualized Cancer Therapy

Academic Radiology

Volumn 14, Issue 4, 2007, Pages 398-405

  Mankoff, David A ^a,b   O'Sullivan, Finbarr ^c   Barlow, William E ^d   Krohn, Kenneth A ^b  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL STUDY; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HUMAN; MEDICAL RESEARCH; MOLECULAR IMAGING; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; THYROID CANCER; TREATMENT RESPONSE;

BIOMEDICAL RESEARCH; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOGRAPHY, INTERVENTIONAL; TUMOR MARKERS, BIOLOGICAL;

EID: 33947109920     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2007.01.005     Document Type: Article

References (44)

1. Kaklamani V., and O'Regan R.M. New targeted therapies in breast cancer. Semin Oncol 31 2 Suppl 4 (2004) 20-25
2. Sawyers C.L. Making progress through molecular attacks on cancer. Cold Spring Harb Symp Quant Biol 70 (2005) 479-482
3. Beckman R.A., and Loeb L.A. Genetic instability in cancer: Theory and experiment. Semin Cancer Biol 15 6 (2005) 423-435
4. Aboagye E.O., and Price P.M. Use of positron emission tomography in anticancer drug development. Investig New Drugs 21 2 (2003) 169-181
5. Kelloff G.J., Hoffman J.M., Johnson B., Scher H.I., Siegel B.A., Cheng E.Y., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11 8 (2005) 2785-2808
6. Kelloff G.J., Krohn K.A., Larson S.M., Weissleder R., Mankoff D.A., Hoffman J.M., et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11 22 (2005) 7967-7985
7. Alessio A.M., Kinahan P.E., Cheng P.M., Vesselle H., and Karp J.S. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am 42 6 (2004) 1017-1032
8. Leach M.O., Brindle K.M., Evelhoch J.L., Griffiths J.R., Horsman M.R., Jackson A., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 92 9 (2005) 1599-1610
9. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47 6 (2006) 1059-1066
10. Lehman C.D. Screening MRI for women at high risk for breast cancer. Semin Ultrasound CT MR 27 4 (2006) 333-338
11. Warner E., Plewes D.B., Hill K.A., Causer P.A., Zubovits J.T., Jong R.A., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 11 (2004) 1317-1325
12. Hartwell L., Mankoff D., Paulovich A., Ramsey S., and Swisher E. Cancer biomarkers: A systems approach. Nat Biotechnol 24 8 (2006) 905-908
13. Pinder S.E., Wencyk P., Sibbering D.M., et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival. Br J Cancer 71 (1995) 146-149
14. Sledge G.J., and McGuire W. Steroid hormone receptors in human breast cancer. Adv Cancer Res 38 (1983) 61-75
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
16. Scher H.I., Morris M.J., Kelly W.K., Schwartz L.H., and Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 11 14 (2005) 5223-5232
17. Yarden Y. The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4 (2001) S3-S8
18. Eary J.F., O'Sullivan F., Powitan Y., et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis. Eur J Nucl Med Mol Imaging 29 9 (2002) 1149-1154
19. 18F]Fluoro-deoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23 34 (2005) 8828-8834
20. 18F]-D-glucose. Cancer 1 (1998) 2227-2234
21. Patronas N.J., Di Chiro G., Kufta C., et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62 (1985) 816-822
22. 18F-FDG PET in glioblastoma multiforme: Prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 43 12 (2002) 1667-1673
23. Vansteenkiste J., Fischer B.M., Dooms C., and Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: Systematic review. Lancet Oncol 5 9 (2004) 531-540
24. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91 2 (2006) 498-505
25. 60Cu-ATSM: relationship to therapeutic response: A preliminary report. Int J Radiat Oncol Biol Phys 55 5 (2003) 1233-1238
26. Rajendran J.G., Schwartz D.L., O'Sullivan J., Peterson L.M., Ng P., Scharnhorst J., et al. Tumor hypoxia imaging with F-18 FMISO PET in head and neck cancer: Value of pre-therapy FMISO uptake in predicting survival. Clin Cancer Res 5 12 (2006) 5435-5441
27. Campbell F.C., Elston C.W., Blamey R.W., et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1 (1981) 1317-1319
28. Cascinu S., Aschele C., Barni S., Debernardis D., Baldo C., Tunesi G., et al. Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5 8 (1999) 1996-1999
29. Pegram M.D., Konecny G.E., O'Callaghan C., Beryt M., Pietras R., and Slamon D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96 10 (2004) 739-749
30. Linden H.M., Stekhova S.A., Link J.M., Gralow J.R., Livingston R.B., Ellis G.K., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 18 (2006) 2793-2799
31. Mortimer J.E., Dehdashti F., Siegel B.A., Trinkaus K., Katzenellenbogen J.A., and Welch M.J. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19 11 (2001) 2797-2803
32. Dimitrakopoulou-Strauss A., Strauss L.G., Schlag P., et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 39 7 (1998) 1197-1202
33. Wolf W., Presant C.A., and Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev 41 1 (2000) 55-74
34. Perik P.J., Lub-De Hooge M.N., Gietema J.A., van der Graaf W.T., de Korte M.A., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24 15 (2006) 2276-2282
35. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., and Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22 6 (2004) 701-706
36. Welch D.R. Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res 6 2 (2004) 61-64
37. Motzer R.J., Hoosen S., Bello C.L., and Christensen J.G. Sunitinib malate for the treatment of solid tumours: A review of current clinical data. Expert Opin Investig Drugs 15 5 (2006) 553-561
38. Bast Jr. R.C., Ravdin P., Hayes D.F., Bates S., Fritsche Jr. H., Jessup J.M., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 6 (2001) 1865-1878
39. Mankoff D.A., Dunnwald L.K., Gralow J.R., Ellis G.K., Schubert E.K., Charlop A.W., et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol 29 7 (2002) 719-727
40. Mankoff D.A., Dunnwald L.K., Gralow J.R., Ellis G.K., Drucker M.J., and Livingston R.B. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium-99m]-sestamibi scintimammography. Cancer 85 (1999) 2410-2423
41. 99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 103 4 (2005) 680-688
42. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39 14 (2003) 2012-2020
43. Blankenberg F., Ohtsuki K., and Strauss H.W. Dying a thousand deaths. Radionuclide imaging of apoptosis. Q J Nucl Med 43 2 (1999) 170-176
44. Mankoff D.A., Shields A.F., and Krohn K.A. PET imaging of cellular proliferation. Radiol Clin North Am 43 1 (2005) 153-167